Skip to Content
Jill  Gilbert

Jill Gilbert, M.D.

Associate Professor of Medicine (Hematology/Oncology)
Director, Hematology/Oncology Fellowship Program
Medical Oncologist

  • Appointments
    Physicians: 1-877-936-8422
  • Clinical Trials Information
  • Other Telephone Numbers
    Henry-Joyce Cancer Clinic
    (615) 936-8422 or 1 (877) 936-8422

  • Faxes
    Henry-Joyce Cancer Clinic Fax
    (615) 343-8668
    Office Fax
  • Addresses
    Henry-Joyce Cancer Clinic
    1301 Medical Center Drive, Suite 1710
    Nashville, Tennessee 37232-7415

    Vanderbilt University Medical Center
    777 Preston Research Building
    2220 Pierce Avenue
    Nashville, TN 37232-6307

Dr. Gilbert is a medical oncologist who specializes in head and neck cancer as well as thyroid cancer. She will primarily be involved in developing clinical trials of novel therapeutic agents for therapy of head and neck and thyroid cancers. Additionally, she is interested in the host immune response in the head and neck cancer survivor and in patients with advanced disease who receive molecularly targeted agents.

As Director of the Hematology/Oncology Fellowship Program, she is extensively involved in training physicians to become specialists in hematology and oncology. In this role, Dr. Gilbert develops and oversees a training program that includes all aspects of clinical hematology/oncology and laboratory-based research opportunities.

  • University of North Carolina, Chapel Hill, North Carolina, BSBiology, May 1990
  • University of Alabama at Birmingham School of Medicine, Magna CumLaude, MD, June 1994
  • Internship, Internal Medicine, University of Alabama atBirmingham, July 1995
  • Residency, Internal Medicine, University of Alabama atBirmingham, July 1997
  • Chief Medical Resident, University of Alabama at Birmingham, May1998
  • Fellow, Medical Oncology and Hematology, Johns Hopkins School ofMedicine, July 2001
  • Hamm HE, Kaya AI, Gilbert JA, Preininger AM. Linking receptor activation to changes in Sw I and II of Ga proteins. J. Struct. Biol [print-electronic]. 2013 Oct; 184(1): 63-74. PMID: 23466875, PMCID: PMC3726552, PII: S1047-8477(13)00053-1, DOI: 10.1016/j.jsb.2013.02.016, ISSN: 1095-8657.
    Available from:
  • Deng J, Murphy BA, Dietrich MS, Wells N, Wallston KA, Sinard RJ, Cmelak AJ, Gilbert J, Ridner SH. Impact of secondary lymphedema after head and neck cancer treatment on symptoms, functional status, and quality of life. Head Neck [print-electronic]. 2013 Jul; 35(7): 1026-35. PMID: 22791550, PMCID: PMC4017911, DOI: 10.1002/hed.23084, ISSN: 1097-0347.
    Available from:
  • Gilbert J, Lee JW, Argiris A, Haigentz M, Feldman LE, Jang M, Arun P, Van Waes C, Forastiere AA. Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology Group. Head Neck [print-electronic]. 2013 Jul; 35(7): 942-8. PMID: 22791234, PMCID: PMC3689864, DOI: 10.1002/hed.23046, ISSN: 1097-0347.
    Available from:
  • Cummings AC, Jiang L, Velez Edwards DR, McCauley JL, Laux R, McFarland LL, Fuzzell D, Knebusch C, Caywood L, Reinhart-Mercer L, Nations L, Gilbert JR, Konidari I, Tramontana M, Cuccaro ML, Scott WK, Pericak-Vance MA, Haines JL. Genome-wide association and linkage study in the Amish detects a novel candidate late-onset Alzheimer disease gene. Ann. Hum. Genet. 2012 Sep; 76(5): 342-51. PMID: 22881374, PMCID: PMC3419486, DOI: 10.1111/j.1469-1809.2012.00721.x, ISSN: 1469-1809.
    Available from:
  • Cooperstein E, Gilbert J, Epstein JB, Dietrich MS, Bond SM, Ridner SH, Wells N, Cmelak A, Murphy BA. Vanderbilt Head and Neck Symptom Survey version 2.0: report of the development and initial testing of a subscale for assessment of oral health. Head Neck [print-electronic]. 2012 Jun; 34(6): 797-804. PMID: 22127786, DOI: 10.1002/hed.21816, ISSN: 1097-0347.
    Available from:
  • Compton DL, Gilbert JK, Jenkins JR, Fuchs D, Fuchs LS, Cho E, Barquero LA, Bouton B. Accelerating chronically unresponsive children to tier 3 instruction: what level of data is necessary to ensure selection accuracy?. J Learn Disabil [print-electronic]. 2012 May; 45(3): 204-16. PMID: 22491810, PII: 0022219412442151, DOI: 10.1177/0022219412442151, ISSN: 1538-4780.
    Available from:
  • Gilbert J, Rudek MA, Higgins MJ, Zhao M, Bienvenu S, Tsottles N, Chaudhry MA, Wahl R, Forastiere A, Gillison M. A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck. Clin. Cancer Res [print-electronic]. 2012 Mar 3/15/2012; 18(6): 1735-42. PMID: 22271880, PMCID: PMC3306472, PII: 1078-0432.CCR-11-2544, DOI: 10.1158/1078-0432.CCR-11-2544, ISSN: 1078-0432.
    Available from:
  • Preininger AM, Kaya AI, Gilbert JA, Busenlehner LS, Armstrong RN, Hamm HE. Myristoylation exerts direct and allosteric effects on Ga conformation and dynamics in solution. Biochemistry [print-electronic]. 2012 Mar 3/6/2012; 51(9): 1911-24. PMID: 22329346, PMCID: PMC3312377, DOI: 10.1021/bi201472c, ISSN: 1520-4995.
    Available from:
  • Gilbert J, Haman KL, Dietrich MS, Blakely RD, Shelton RC, Murphy BA. Depression in patients with head and neck cancer and a functional genetic polymorphism of the serotonin transporter gene. Head Neck [print-electronic]. 2012 Mar; 34(3): 359-64. PMID: 21604315, DOI: 10.1002/hed.21744, ISSN: 1097-0347.
    Available from:
  • Gilbert J, Murphy B, Dietrich MS, Henry E, Jordan R, Counsell A, Wirth P, Yarbrough WG, Slebos RJ, Chung CH. Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer. Cancer [print-electronic]. 2012 Feb 2/15/2012; 118(4): 1007-13. PMID: 21766301, DOI: 10.1002/cncr.26364, ISSN: 1097-0142.
    Available from:
  • Horn L, Koehler E, Gilbert J, Johnson DH. Factors associated with the career choices of hematology and medical oncology fellows trained at academic institutions in the United States. J. Clin. Oncol [print-electronic]. 2011 Oct 10/10/2011; 29(29): 3932-8. PMID: 21911716, PMCID: PMC3189092, PII: JCO.2011.35.8663, DOI: 10.1200/JCO.2011.35.8663, ISSN: 1527-7755.
    Available from:
  • Gilbert JK, Compton DL, Kearns DM. Word and Person Effects on Decoding Accuracy: A New Look at an Old Question. J Educ Psychol. 2011 May 5/1/2011; 103(2): 489-507. PMID: 21743750, PMCID: PMC3129854, DOI: 10.1037/a0023001, ISSN: 0022-0663.
    Available from:
  • Diaz R, Jaboin JJ, Morales-Paliza M, Koehler E, Phillips JG, Stinson S, Gilbert J, Chung CH, Murphy BA, Yarbrough WG, Murphy PB, Shyr Y, Cmelak AJ. Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys [print-electronic]. 2010 Jun 6/1/2010; 77(2): 468-76. PMID: 19577867, PII: S0360-3016(09)00764-0, DOI: 10.1016/j.ijrobp.2009.05.018, ISSN: 1879-355X.
    Available from:
  • Compton DL, Fuchs D, Fuchs LS, Bouton B, Gilbert JK, Barquero LA, Cho E, Crouch RC. Selecting At-Risk First-Grade Readers for Early Intervention: Eliminating False Positives and Exploring the Promise of a Two-Stage Gated Screening Process. J Educ Psychol. 2010 May 5/1/2010; 102(2): 327-40. PMID: 20689725, PMCID: PMC2913521, DOI: 10.1037/a0018448, ISSN: 0022-0663.
    Available from:
  • Chung CH, Aulino J, Muldowney NJ, Hatakeyama H, Baumann J, Burkey B, Netterville J, Sinard R, Yarbrough WG, Cmelak AJ, Slebos RJ, Shyr Y, Parker J, Gilbert J, Murphy BA. Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann. Oncol [print-electronic]. 2010 Apr; 21(4): 864-70. PMID: 19850643, PMCID: PMC2844946, PII: mdp390, DOI: 10.1093/annonc/mdp390, ISSN: 1569-8041.
    Available from:
  • Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, Murphy B, Caprioli RM, Carbone DP, Cohen EE. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol. Biomarkers Prev [print-electronic]. 2010 Feb; 19(2): 358-65. PMID: 20086114, PMCID: PMC2846615, PII: 1055-9965.EPI-09-0937, DOI: 10.1158/1055-9965.EPI-09-0937, ISSN: 1538-7755.
    Available from:
  • Murphy BA, Dietrich MS, Wells N, Dwyer K, Ridner SH, Silver HJ, Gilbert J, Chung CH, Cmelak A, Burkey B, Yarbrough WG, Sinard R, Netterville J. Reliability and validity of the Vanderbilt Head and Neck Symptom Survey: a tool to assess symptom burden in patients treated with chemoradiation. Head Neck. 2010 Jan; 32(1): 26-37. PMID: 19626644, DOI: 10.1002/hed.21143, ISSN: 1097-0347.
    Available from:
  • Hatakeyama H, Cheng H, Wirth P, Counsell A, Marcrom SR, Wood CB, Pohlmann PR, Gilbert J, Murphy B, Yarbrough WG, Wheeler DL, Harari PM, Guo Y, Shyr Y, Slebos RJ, Chung CH. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS ONE. 2010; 5(9): e12702. PMID: 20856931, PMCID: PMC2938338, DOI: 10.1371/journal.pone.0012702, ISSN: 1932-6203.
    Available from:
  • Schnetz-Boutaud NC, Anderson BM, Brown KD, Wright HH, Abramson RK, Cuccaro ML, Gilbert JR, Pericak-Vance MA, Haines JL. Examination of tetrahydrobiopterin pathway genes in autism. Genes Brain Behav [print-electronic]. 2009 Nov; 8(8): 753-7. PMID: 19674121, PMCID: PMC2784255, PII: GBB521, DOI: 10.1111/j.1601-183X.2009.00521.x, ISSN: 1601-183X.
    Available from:
  • Anderson BM, Schnetz-Boutaud N, Bartlett J, Wright HH, Abramson RK, Cuccaro ML, Gilbert JR, Pericak-Vance MA, Haines JL. Examination of association to autism of common genetic variationin genes related to dopamine. Autism Res. 2008 Dec; 1(6): 364-9. PMID: 19360691, PMCID: PMC2947794, DOI: 10.1002/aur.55, ISSN: 1939-3806.
    Available from: